SEC charges pharma CEO, 2 companies with offering fraud
By 
Adrianne Appel2022-09-30T19:42:00
The Securities and Exchange Commission (SEC) charged Paul Edalat and two pharmaceuticals companies he controlled with engaging in a fraudulent investment scheme.
Edalat has been chief executive officer, controlling shareholder, and chairman of the board at Vivera Pharmaceuticals since April 2018. During that time, he was also controlling shareholder and chairman of the board at Sentar Pharmaceuticals.
From May 2018 until June 2020, Vivera raised about $6.6 million from 63 investors through a private placement memorandum that claimed Vivera owned an exclusive global license for a method of delivering CBD and THC, both derived from cannabis, under the tongue, according to the SEC’s complaint, filed Friday in U.S. District Court for the Central District of California.
Related articles
-
WebcastCPE Webcast: Risky Business: Navigating Compliant Innovation Amid Deregulation
The compliance landscape has entered unprecedented territory, characterized by what industry experts describe as “deregulation on top of deregulation” – a dangerous departure from the traditional regulatory cycle that historically provided stability and clear guidance.
-
ArticleJPMorgan Chase pays $330M to settle Malaysian fund allegations
JPMorgan Chase has agreed to pay $330 million to settle allegations about its role in the massive, decades-long theft of Malaysian’s 1MDB state investment fund, the bank says. An estimated $4.5 billion was robbed from the 1MDB fund, from 2009-2014, in a scheme led by Malaysian financier, Jho Low, former ...
-
ArticleOCC lifts AML consent order on Anchorage Digital
Crypto platform Anchorage Digital has been freed of a consent order originally issued by the Treasury Department for anti-money laundering failures.
More from Regulatory Enforcement
-
News BriefDOJ charges California fintech executives in $248M fraud involving falsified documents
The co-founders of a California financial tech and sustainability services company defrauded investors and lenders of $248 million, according to the Department of Justice.
-
News BriefFTC complaint accuses LA Fitness parent companies of blocking easy membership exits
The Federal Trade Commission filed a complaint against LA Fitness’ parent companies, citing difficulties canceling memberships, a month after a court blocked the agency’s click-to-cancel rule.
-
ArticleJudge orders CVS to pay nearly $290M for Medicare false claims
CVS’s Caremark division knowingly overcharged Medicare for prescription drugs and must pay nearly $290 million, a Pennsylvania federal judge has ordered.